Jubilant Pharmova per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹22.23₹25.15₹52.99₹4.87−₹3.83
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹22.17₹25.08₹52.85₹4.86−₹3.83
₹448.91₹448.91₹395.88₹343.92₹339.36
₹544.83₹524.03₹457.88₹424.23₹394.83
—₹77.65₹67.85₹61.47₹41.53
−₹14.07−₹14.07−₹2.75₹4.66−₹9.67
—₹5.03₹5.04₹5.05₹5.03
15.815.815.815.815.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JUBLPHARMA₹937.00

Jubilant Pharmova Ltd.

· Pharma & Health
₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹14,805 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-3.834.8752.9925.1522.23
Diluted EPS-3.834.8652.8525.0822.17
Book Value per Share339.36343.92395.88448.91448.91
Revenue per Share394.83424.23457.88524.03544.83
Cash Flow per Share41.5361.4767.8577.65—
Free Cash Flow per Share-9.674.66-2.75-14.07-14.07
Dividends per Share5.035.055.045.03—
Shares Outstanding (cr)15.915.815.815.815.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.